ロード中...
Effect of Tipranavir-Ritonavir on Pharmacokinetics of Raltegravir
Raltegravir (RAL) is a novel and potent human immunodeficiency virus type 1 integrase inhibitor that is predominantly metabolized via glucuronidation. The protease inhibitor combination tipranavir (TPV) at 500 mg and ritonavir (RTV) at 200 mg (TPV-RTV) has inhibitory and inductive effects on metabol...
保存先:
| 主要な著者: | , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society for Microbiology (ASM)
2009
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2704640/ https://ncbi.nlm.nih.gov/pubmed/19398643 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01486-08 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|